↓ Skip to main content
What is this page? Embed badge

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years

Overview of attention for article published in Journal of Clinical Lipidology, June 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

guideline
1 clinical guideline source

Readers on

mendeley
64 Mendeley
So far, Altmetric has seen 1 Guideline that references this research output.

Inhibidores de la proproteína convertasa subtilisina/kexina tipo 9 (iPCSK9) en la prevención secundaria de episodios vasculares en pacientes con ictus isquémico: Documento de consenso y aplicaciones prácticas

Clinical guideline published by Spanish Society of Neurology (SEN) on

The Spanish Society of Neurology (SEN) is a prominent scientific organization founded in 1949, comprising around 3,500 members, primarily neurologists. It focuses on advancing neurological science through guidelines, protocols, and educational resources for professionals in the field.

This page shows the most recent posts that mention this research output. Click here to find out how to access more activity.